A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic ...
Nov 28, 2013
0
0
The risks of developing kidney failure and a calcium deficiency from the popular osteoporosis drug zoledronic acid are extremely rare, according to researchers at Loyola University Health System (LUHS). These findings were ...
Oct 31, 2013
0
0
Researchers at the University of Georgia have discovered that a combination of two commonly prescribed drugs used to treat high cholesterol and osteoporosis may serve as the foundation of a new treatment for toxoplasmosis, ...
Oct 17, 2013
0
0
(HealthDay)—Women with postmenopausal osteoporosis treated with zoledronic acid show an early increase in serum levels of the negative regulator of bone formation, sclerostin, that return close to baseline after 360 days, ...
Apr 29, 2013
0
0
Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal ...
Apr 17, 2013
0
0
(HealthDay)—For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a study published in the Nov. ...
Nov 2, 2012
0
0
Treatment with denosumab resulted in a greater reduction in skeletal-related events in patients with breast cancer that spread to the bones compared with zoledronic acid, while also maintaining health-related quality of life, ...
Aug 14, 2012
0
0
A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, ...
Oct 10, 2011
0
0
A new research paper, titled "In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers," was published on the cover of Aging
May 15, 2023
0
32
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or bone marrow lesion (BML) ...
Jun 15, 2018
0
2
